Table 2.
Subgroup analysis for the clinical factors affecting early recurrence in patients who received CRT preoperatively (n = 51) or upfront surgery (n = 64)
| Patients who received CRT preoperatively (n = 51) | Patients who received upfront surgery (n = 64) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group E (n = 11)b | Group NE (n = 40)c | P-value | HR | 95% CI | P-value※ | Group E (n = 23)b | Group NE (n = 41)c | P-value | HR | 95% CI | P-value※ | ||
| BMIa | < 21.5 | 7 (70%) | 15 (39%) | 0.085 | |||||||||
| CRPa | ≧ 0.19 | 13 (72%) | 18 (46%) | 0.066 | |||||||||
| CA19–9a | ≧ 173 | 14 (61%) | 15 (38%) | 0.088 | |||||||||
| NLRa | ≧ 4.65 | 6 (60%) | 9 (25%) | 0.037 | 2 (20%) | 1 (4%) | 0.098 | ||||||
| Lymphocyte counta | ≦ 1648 | 15 (94%) | 25 (66%) | 0.032 | |||||||||
| Postoperative CA19–9 normalization | No | 6 (86%) | 5 (22%) | 0.002 | 83.36 | 3.32–2095.0 | 0.007 | 11 (79%) | 4 (18%) | < 0.001 | 39.26 | 3.65–422.10 | 0.002 |
| Postoperative ACT | No | 5 (45%) | 7 (18%) | 0.053 | 13 (57%) | 5 (12%) | < 0.001 | 15.53 | 2.51–96.04 | 0.003 | |||
| Tumor sizea | ≧ 3.0 | 16 (70%) | 16 (43%) | 0.047 | |||||||||
| PALN metastasis | Positive | 1 (10%) | 0 (0%) | 0.052 | |||||||||
| LN metastasis | Positive | 8 (73%) | 17 (43%) | 0.076 | |||||||||
| ly | Positive | 9 (82%) | 21 (53%) | 0.080 | |||||||||
| S | Positive | 10 (91%) | 17 (43%) | 0.004 | 13.08 | 1.25–137.46 | 0.032 | ||||||
| A | Positive | 2 (18%) | 1 (3%) | 0.050 | |||||||||
| PL | Positive | 7 (64%) | 13 (33%) | 0.061 | |||||||||
| Resection status | R1 | 5 (21%) | 2 (5%) | 0.038 | 10.03 | 0.84–118.82 | 0.067 | ||||||
※; logistic regression analysis, Variables with P ≦ 0.10 are shown in this table
aThe cutoff values of BMI, CRP, NLR, lymphocyte count and tumor size were set by drawing a receiver operating characteristic curve
bRecurrence within 6 months after surgery
cRecurrence at more than 6 months after surgery